Testing a New Breast Cancer Drug for Women Who Can't Tolerate Current Therapy
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests giredestrant, a new hormone-blocking medication, in postmenopausal women with early-stage ER+ breast cancer who have experienced intolerable side effects from their current aromatase inhibitor therapy. The trial will measure how well you tolerate this new drug and how it affects your quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are postmenopausal at the time you sign up for the study
- You have been diagnosed with ER+/HER2- early breast cancer (Stage I–III) that was confirmed by a pathology report
- You have taken an aromatase inhibitor (anastrozole, exemestane, or letrozole) for at least 6 months total, and continuously for at least 3 months right before enrolling
- Your current aromatase inhibitor is causing Grade 2 or 3 side effects (moderate to severe symptoms) that you and your doctor agree are intolerable
- You have completed surgery and/or radiation therapy for your breast cancer, and any chemotherapy if it was recommended
- You have an ECOG performance status of 0 or 1, meaning you are well enough to carry out normal daily activities (with possibly some limitations)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests several combinations of cancer medicines to slow or control ER-positive breast cancer that has returned or progressed. It also checks safety and whether tumor or blood biomarkers can help match the right treatment to the right person.
This Phase 1 study tests a new drug (RGT-419B), given alone or with hormone (endocrine) therapy, in people with advanced ER-positive, HER2-negative breast cancer that has progressed after standard treatments. It looks mainly at safety and early signs of how well the treatment may work.
This trial tests a new oral hormone therapy, giredestrant, against a standard hormone therapy (fulvestrant) when both are given with a CDK4/6 inhibitor. It is for people with advanced ER-positive, HER2-negative breast cancer that has come back after initial hormone therapy, and who have not yet had other treatments for advanced disease.
This trial tests whether switching to a different aromatase inhibitor or using standard treatments works better for managing side effects in breast cancer survivors. It aims to help you stay on hormone therapy longer with fewer discomforts.
This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.
This trial tests a combination of two oral medications (abemaciclib and giredestrant) given before surgery to women with a common type of early breast cancer (hormone receptor-positive, HER2-negative). The goal is to see if this treatment can shrink the tumor before surgery.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.